Eylea (aflibercept) Injection

Information for Wet AMD Patients Being Treated with Eylea

If You Or A Loved One Has Wet AMD You Are Not Alone

If you or a loved one has been diagnosed with the neovascular or "wet" form of Age-related Macular Degeneration (AMD), it may be difficult to accept. Although wet AMD is a life-changing condition, by consulting your doctor, you can learn that there are medications available and steps you can take to minimize the effect of your condition.

More than 1.75 million Americans have wet AMD.1 Scientific discoveries have led to treatments that may help patients with wet AMD.2-5

IMPORTANT PRESCRIBING INFORMATION FOR EYLEA® (aflibercept) INJECTION

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with wet AMD. The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (4 weeks) injections. EYLEA may be dosed once per month, but additional benefit was not seen with this dosing plan.

IMPORTANT SAFETY INFORMATION FOR EYLEA® (aflibercept) INJECTION

EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept. As with all medications, EYLEA can cause side effects.

Injection into the eye can result in an infection in the eye and retinal detachment. Inflammation in the eye has been reported with the use of EYLEA.

In some patients, injections with EYLEA may trigger a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.

Serious side effects related to the injection procedure are rare but can occur including infection inside the eye, retinal detachment, cataract, increased pressure in the eye, and vitreous detachment.

It is important that you contact your doctor right away if you think you might be experiencing any side effects.

EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call1-800-FDA-1088.

References:

  1. Prevalence of age-related macular degeneration in the United States. National Eye Institute Web site.
    http://www.nei.nih.gov/eyedata/pbd4.asp. Accessed on August 5, 2011.
  2. Age-related macular degeneration: what you should know. National Eye Institute Web site.
    http://www.nei.nih.gov/health/maculardegen/nei_wysk_AMD. Accessed June 7, 2011.
  3. Wet macular degeneration. Mayo Clinic Web site.
    http://www.mayoclinic.com/health/wet-macular-degeneration/DS01086/METHOD=print. Accessed June 7, 2011.
  4. Age related macular degeneration. Retina Foundation and Eye Research Center Web site.
    http://www.retinafoundation.com/age_related_macular_degeneration.html. Accessed August 5, 2011.
  5. Facts about age-related macular degeneration. National Eye Institute Web site.
    http://www.nei.nih.gov/health/maculardegen/armd_facts.asp. Accessed June 7, 2011.

To view the publication, you will be directed to a third-party site that is not owned or controlled by Regeneron Pharmaceuticals, Inc. This link is provided as a resource to the viewer. The use of third-party web sites is at your own risk, and is subject to the terms and conditions of such sites.

Cancel